Business Wire

Galderma to Present New Data From Leading Aesthetics Portfolio and Launch * RESTYLANE ® EYELIGHT™ at AMWC 2021


Galderma today announced new results from its robust pipeline and portfolio of dermal fillers and toxin injections. Eleven e-posters from Galderma-sponsored and investigator-initiated trials have been accepted at the upcoming Aesthetic & Anti-Aging Medicine World Congress (AMWC), taking place in Monaco and virtually on September 16–18, 2021.

Data for SCULPTRA® (injectable poly-L-lactic acid) will explore the effectiveness and safety of two different dilutions (8mL versus 5mL) at 48 weeks for the correction of nasolabial fold wrinkles. Earlier this year, the administration procedure for SCULPTRA was updated in Europe, allowing for higher reconstitution volumes of 5-8mL (previously 5mL). These latest results serve to support the new protocol, which offers a faster and more convenient approach to injecting dermal fillers.

Further data will evaluate the effectiveness and safety of ALLUZIENCE® (liquid botulinum toxin type A) versus placebo after six months for the correction of glabellar (frown) lines. All currently approved botulinum toxin type A products in Europe come in powder form and require reconstitution before use.1 ALLUZIENCE—the first ready-to-use liquid formulation licensed in Europe—has been designed to deliver outstanding precision and performance, with a formulation developed using innovative new production technologies.1,2

“Our strong presence at AMWC this year underscores our unwavering commitment to driving aesthetics innovation. We understand that everyone’s skin is unique, and we embrace these differences to offer cutting-edge treatments that make people look and feel great. As we advance dermatology for every skin story, we are excited to be delivering novel solutions across our portfolio.”


Taking the opportunity to engage with a variety of aesthetics and anti-aging experts, Galderma will host a sponsored symposium on Thursday, September 16, 2021, from 14:00-16:00 CEST in the prestigious Prince Pierre Auditorium. The interactive session, First Impressions – From Theory to Practice, will involve assessment with patient pictures, audience participation and live injections, led by a panel of multidisciplinary speakers covering the nose, skin and lips. More information and access to the event will be available to all registered congress participants.

The sponsored symposium will be followed on Friday, September 17, 2021, with a bespoke event, For Your Eyes Only, to launch RESTYLANE® EYELIGHT, a new solution to combat under-eye shadows. The under-eye region is one of the first parts of the face to show signs of aging. This makes RESTYLANE EYELIGHT a major milestone for helping people look less tired and more rested, in addition to helping them feel their best.3,4 From 18:30-20:30 CEST, a world-renowned faculty will deliver an interactive agenda exploring the new opportunity and value of RESTYLANE EYELIGHT to clinical practice. Access to the event is invitation-only.

Additional data showcasing the strength and depth of Galderma’s pipeline and portfolio will be available throughout AMWC 2021. The complete list of 11 e-posters that have been accepted for presentation are:





A randomized study on safety and effectiveness of a biostimulatory poly-L-lactic acid injectable implant after changes in reconstitution – Palm M., et al.

Abstract #2343


Treatment of moderate-to-severe glabellar lines using ready-to-use liquid abobotulinumtoxinA: Pooled data from two double-blind, randomized, placebo-controlled Phase III studies – Kestemont P., et al.

Abstract #2340


Long-lasting improvement of glabellar lines using ready-to-use liquid abobotulinumtoxinA: Post hoc analysis of a double-blind, randomized, placebo-controlled Phase III study – Kestemont P., et al.

Abstract #2341


A randomized, double-blind, placebo-controlled study of a new dilution and injection volume of abobotulinumtoxinA for treatment of glabellar lines – Schlessinger J., et al.

Abstract #2324


A randomized, dose-escalating, double-blind study to evaluate abobotulinumtoxinA for the treatment of moderate-to-severe glabellar lines – Joseph J., et al.

Abstract #2462


Subject satisfaction with abobotulinumtoxinA for moderate-to-severe glabellar lines: A randomized, dose-escalating, double-blind study – Dayan S., et al.

Abstract #2461


Subject-relevant outcomes of on-label 50U abobotulinumtoxinA treatment for moderate-to-severe glabellar lines across three individual trials – Cox SE., et al.

Abstract #2460


Subject satisfaction with two treatments a year (every six months) of abobotulinumtoxinA is high among both previously treated and toxin-naive cohorts – Cohen J., et al.

Abstract #2527


Millennial subject satisfaction with two treatments of abobotulinumtoxinA a year – Cohen J., et al.

Abstract #2529


A randomized, controlled, evaluator-blinded study of HA-RD for chin augmentation and correction of chin retrusion – Moradi A., et al.

Abstract #2323


A randomized, evaluator-blinded, comparator-controlled study to evaluate HA-RV for cheek augmentation and correction of midface contour deficiencies – Moradi A., et al.

Abstract #2339

For more information, the AMWC 2021 program is available here:

* In September 2021, BeNeLux, France, Germany, the Nordics, Portugal, Spain, and Switzerland launched RESTYLANE EYELIGHT

**DYSPORT is marketed as AZZALURE® in the EU for the treatment of glabellar lines

About Galderma
Galderma is the world’s largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes. Because we understand that the skin we’re in shapes our life stories, we are advancing dermatology for every skin story. For more information:

SCULPTRA works to stimulate the skin’s own collagen production5 and is suitable for increasing the volume of depressed areas, particularly to correct skin depressions such as skin creases, wrinkles, folds and scars, and for signs of skin aging.6 SCULPTRA is also suitable for large volume corrections of the signs of facial fat loss (lipoatrophy).6

SCULPTRA is an injectable biostimulator containing microparticles of poly-L-lactic acid (PLLA) which gradually revitalizes the skin’s structural foundation, providing natural-looking, long-term results for up to 25 months.7 SCULPTRA was first approved in 1999 in Europe and it is currently available in more than 40 countries globally.

ALLUZIENCE (liquid botulinum toxin type A) is the first ready-to-use BoNT-A liquid neuromodulator formulation to be introduced in Europe. ALLUZIENCE should only be administered by a physician with appropriate qualifications and expertise in this treatment using the required equipment.2 Dosing and treatment intervals depend on assessment of the individual patient’s response.2 The treatment interval should be no more frequent than every three months.2 For more information, please see the ALLUZIENCE Summary of Product Characteristics.

ALLUZIENCE is a product under license from Ipsen. ALLUZIENCE is a registered trademark of Ipsen. Galderma has an exclusive license from Ipsen to develop, promote and distribute ALLUZIENCE in the approved indication in Europe (excluding Czech Republic, Slovakia, Greece, Lithuania, Estonia, Latvia and Hungary).

About Galderma’s collaboration with Ipsen
DYSPORT (abobotulinumtoxinA) is a prescription injection for temporary improvement in the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults less than 65 years of age.8 DYSPORT is also marketed as AZZALURE in the EU,8 for the treatment of glabellar lines with more than 40 million treatments in the EU and U.S. combined and with approvals in 74 countries.

DYSPORT is manufactured by Ipsen, a global specialty-driven pharmaceutical company. Since 2009, Galderma and Ipsen have had a strategic partnership under which Galderma has promoted and distributed Ipsen's botulinum toxin type A products in aesthetic indications. The Ipsen-Galderma strategic partnership now covers China, the United States, the European Union, Australia, South Korea, Canada, Brazil, Argentina and several other countries. Ipsen continues to promote DYSPORT within certain therapeutic indications in countries around the world.

About Galderma’s RESTYLANE portfolio
RESTYLANE is the original non-animal stabilized hyaluronic acid filler, with over 25 years of achievement and over 50 million treatments worldwide.9 NASHA™ and OBT™ technologies make RESTYLANE the world’s most diverse range of fillers to deliver truly individualized results.10,11



1 Ascher B, Rzany B, Kestemont P, et al. Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo Controlled Study of a Single Treatment, Ready-to Use Toxin for Moderate-to-Severe Glabellar Lines. Aesthet Surg J. 2020;40(1):93–104.
2 Alluzience. Summary of Product Characteristics.
3 Data on file (MA-48305).
4 Verpaele A, Strand A. Restylane SubQ, a non-animal stabilized hyaluronic acid gel for soft tissue augmentation of the mid- and lower face. Aesthetic Surgery Journal. 2006 Jan;26(1):S10–7.
5 Bohnert K et al. Randomized, controlled, multicentered, double-blind investigation of injectable poly-L-lactic acid for improving skin quality. Plast Reconstr Surg 2019;127(4):1684–92.
6 Sculptra IFU. 2018.
7 Brown SA et al. Subject global evaluation and subject satisfaction using injectable poly-L-lactic acid versus human collagen for the correction of nasolabial fold wrinkles. Plast Reconstr Surg 2011;127(4):1684–92.
8 Azzalure. Summary of Product Characteristics.
9 Data on file (MA-39680).
10 Data on file (MA-33939).
11 Öhrlund A. Poster presented at AMWC 2019.

Job code: GL-RES-2100312
Date of preparation: September 2021

To view this piece of content from, please give your consent at the top of this page.

Contact information

Media contacts
Lauren Starr, Head of Franchise Communications, Galderma
Phone: +41 79 771 52 45

Barney Mayles, Director, OPEN Health
Phone: +44(0) 7936 768 568

About Business Wire

Business Wire
Business Wire

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF Appoints Glenn Richter as Executive Vice President and Chief Financial Officer16.9.2021 22:15:00 CEST | Press release

IFF (NYSE: IFF) today announced that Glenn Richter, an accomplished financial executive with nearly three decades of experience overseeing finance and corporate strategy for multinational companies, has been appointed Executive Vice President and Chief Financial Officer, effective September 27, 2021. Mr. Richter was most recently Chief Financial Officer of TIAA, a leading global provider of financial services with $1.3 trillion in assets under management. He succeeds Rustom Jilla, who will be leaving the Company following a period of transition. With this appointment, Mr. Richter becomes a member of IFF’s Executive Committee and will be based in the Company’s New York City headquarters. “We are delighted to welcome Glenn to our leadership team. His experience leading large, global finance departments, implementing multi-year strategic productivity initiatives and managing transformative integrations will be a tremendous asset to our team,” said Andreas Fibig, Chairman and Chief Executi

The NAGA Group AG: Christian Angermayer's Apeiron Investment Group and Fosun Join Forces to Further Drive NAGA Growth16.9.2021 22:00:00 CEST | Press release

NAGA Group AG (XETRA: N4G, ISIN: DE000A161NR7), provider of the social network for trading, cryptocurrencies and payments, announces its largest equity financing round to date and welcomes Apeiron Investment Group Ltd, the private investment company of entrepreneur and investor Christian Angermayer, and Igor Lychagov, founder of Exness (one of the world's largest brokerage firms with a monthly trading volume of USD 1 trillion) as new strategic and long-term investors. Hauck & Aufhäuser acted as sole bookrunner in the transaction. In addition to participating in the capital increase, Apeiron has entered into a share purchase agreement with its Elevat3 strategy, operating in partnership with Peter Thiel's Founders Fund, to purchase a block of shares from FOSUN Group and is in negotiations to acquire additional shares from other shareholders. These transactions are subject to regulatory approvals. In total and upon full completion, Apeiron is targeting a stake of approximately 22

Landmark Celebrates 30 Years as the Industry Leader in Personal & Professional Growth, Training and Development16.9.2021 20:00:00 CEST | Press release

Landmark (Landmark Worldwide), established in 1991, celebrates its 30th anniversary with more than three million people across the globe having been positively and powerfully contributed to and empowered by its programs. Marking a related anniversary, it was 50 years ago that the ideas that grew into Landmark were born with the delivery of the first est Training in 1971. As the leader in the personal and professional growth, training and development industry, Landmark’s programs and ideas have empowered people for five decades to dramatically elevate the quality of their lives and, in addition, to impact the areas of their lives that matter most to them. Marketdata Enterprises, Inc., publishers of the definitive report on the personal development industry in the United States, stated in their 2021 report: “Landmark was named one of the top training and development companies in the world by McNeil.” “Landmark is recognized for having one of the best faculty bodies in the bu

ISACA to Host Inaugural ISACA Conference Europe Virtual Event16.9.2021 19:21:00 CEST | Press release

Next month, ISACA will host the first-ever ISACA Conference Europe, an event focused on emerging technologies, best practices, and leadership development. The conference will take place virtually 20-22 October featuring topics for business technology professionals as they navigate their transformational roles. ISACA Conference Europe sessions range from 25-75 minutes in length and provide the opportunity to earn up to 19 continuing professional education credits. Conference tracks focus on IT audit, IT governance, COBIT, CMMI, cybersecurity, privacy, risk, performance improvement, emerging technologies, and leadership development & career management. Sessions will be presented live via ISACA’s virtual conference platform, and many will feature a live Q&A with speakers. Attendees will have extended access to the sessions and content so they may view them at their own pace. Session topics include data ethics laws, blockchain, CMMI V2.0, cloud security, auditing artificial intelligence, q

Virpax ® Pharmaceuticals Announces Closing of $40 Million Public Offering of Common Stock16.9.2021 19:00:00 CEST | Press release

Virpax® Pharmaceuticals Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced the closing of an underwritten public offering of 6,670,000 shares of its common stock at a public offering price of $6.00 per share, for gross proceeds of $40,020,000, before deducting underwriting discounts and offering expenses. In addition, Virpax has granted the underwriters a 45-day option to purchase up to an additional 1,000,500 shares of common stock to cover over-allotments at the public offering price, less the underwriting discount. Virpax intends to use the net proceeds from the offering to fund research and development of the Epoladerm, Probudur, Envelta and AnQlar indications and other development programs, pay fees and expenses associated with the offering, repay outstanding promissory notes issued to the Company’s Chief Executive Officer and pay deferred compensation due to the Company’s Chief Executiv

Verimatrix To Highlight Success In Enabling Secure Virtual Hollywood Events at Variety Entertainment & Technology Summit16.9.2021 17:45:00 CEST | Press release

Regulatory News: Verimatrix, (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that Jon Samsel, Senior Vice President of Marketing, will discuss the value of harnessing security as a differentiator for the M&E industry during the upcoming virtual Variety Entertainment & Technology Summit. On Thursday, September 23, 2021 from 10:50 to 11:20 a.m. Pacific Time, Samsel will take part in a panel alongside Little Cinema Digital CEO Jay Rinsky and moderator Todd Spangler, NY Digital Editor at Variety. Register for free today. Titled, “Security That's Transforming Hollywood: The Little Cinema Digital Story,” the online event serves as an opportunity for attendees to learn how Verimatrix and Little Cinema Digital collaborated to transform the traditional Hollywood movie premiere business into an immersive virtual event platform that breaks down traditional limitations of venue capacities or locations. By leading with security, the comp

Exactech’s Equinoxe® Stemless Shoulder Replacement System Debuts in Europe16.9.2021 16:06:00 CEST | Press release

Exactech, a developer and producer of innovative implants, instrumentation and smart technologies for joint replacement surgery, announced today that the first anatomic total shoulder surgery has been performed in Europe using its bone-conserving, 3D-printed Equinoxe® Stemless Shoulder. Prof. Mark Tauber, MD, PhD, of Athos Klinik in Munich, Germany, performed the first surgery earlier this month. This press release features multimedia. View the full release here: Prof. Mark Tauber, MD, PhD, of Athos Klinik in Munich, Germany performed the first surgery in Europe using Exactech's bone-conserving, 3D-printed Equinoxe® Stemless Shoulder (Photo: Business Wire) “It was wonderful to be the first user of the Exactech Stemless humeral component in Europe,” Tauber said. “I’ve used stemless implants with various systems since 2007, so I know what we are talking about and have to congratulate Exactech for this product. The user-friendly in

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom